CellPoint Diagnostics

United States
San Diego, California, United States
(858)551-8700 ★

Company profile

CellPoint Diagnostics company profile

CellPoint Diagnostics is an early stage company developing diagnostic, monitoring, and molecular analytical tools for cancer. Their novel, proprietary technology captures and analyzes circulating tumor cells ("CTCs") directly from patient blood. Scientific and clinical data have demonstrated that CTCs are derived from the primary tumor, and the assessment of the number of CTCs in the blood has been shown to accurately predict survival for cancer patients. Their goal is to commercialize products that will provide safe, non-invasive "blood-based biopsies" which will present physicians and patients with highly accurate, real-time, individualized clinical information on disease status and treatment response. They intend..... For more information, log in to dureach.com to view the full company profile.

Business identity

Contact email
[email protected]
Phone number
(858)551-8700
Operating status
Active
Company type
For Profit
Employee range
00001-00010 employees
Founded
2006-01-01

Headquarters

Headquarters
San Diego, California, United States
Postal code
92037
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
1
Total equity funding
$11.2M
Last funding
Series A / $11.2M / 2007-10-15
Last equity funding
Series A / $11.2M
Investors
2
Exited on
2008-08-31

Founders and investors

Investors

Mohr Davidow VenturesNorthgate Capital

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.